CaitlinLCostelloMD

PubMed

• Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
  Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Timothy M Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dha...> ;Blood Cancer Journal. 2024 Apr 22
• Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
  Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
• -class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
  Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter, Rafat Abonour, Hans C Lee, Michael Stokes, Kaili Ren, Dawn Marie Stull, Dasha...> ;Future Oncology. 2024 Jan 1
• 11 citations
  Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
  Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, A...> ;Nature Medicine. 2023 Oct 1
• 2 citations
  Newly diagnosed multiple myeloma: making sense of the menu.
  Caitlin L Costello> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
• Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
  Michael A Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C Weisel, Robert M Rifkin, Saad Z Usmani, Roman Hájek, Gordon Cook, Rafat Ab...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Mar 1
• 14 citations
  Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...
  Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, ...> ;Transplantation and Cellular Therapy. 2023 Mar 1
• 1 citations
  Extracorporeal photopheresis for the treatment of chronic graft versus host disease.
  Emin Kansu, David Ward, Amber P Sanchez, Robyn Cunard, Mutlu Hayran, Beril Huseyin, Majella Vaughan, Grace Ku, Peter Curtin, Carolyn Mulroney, Caitlin Costello, Januar...> ;Hematology. 2022 Dec 1
• 2 citations
  Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
  Ashni A. Vora, Phoebe Mondala, Caitlin Costello, A. Robert MacLeod, Leslie Crews> ;STAR Protocols. 2021 May 27
• 19 citations
  Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (...
  Faith E. Davies, Robert M. Rifkin, Caitlin Costello, Gareth J. Morgan, Saad Z. Usmani, Rafat Abonour, Antonio Palumbo, Dorothy Romanus, Roman Hájek, Evangelos Terpos, ...> ;Annals of Hematology. 2021 May 10
• 9 citations
  Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens
  Samantha Phou, Caitlin Costello, Patricia M. Kopko, Elizabeth S. Allen> ;Transfusion. 2021 May 7
• 10 citations
  Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
  Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Jesus G. Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojed...> ;Future Oncology. 2021 Mar 26
• 43 citations
  Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
  Evangelos Terpos, Joseph Mikhael, Roman Hájek, Ajai Chari, Sonja Zweegman, Hans C. Lee, Maria-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gor...> ;Blood Cancer Journal. 2021 Feb 18
• 23 citations
  Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption
  Phoebe Mondala, Ashni A. Vora, Tianyuan Zhou, Elisa Lazzari, Luisa Ladel, Xiaolin Luo, Youngsoo Kim, Caitlin Costello, Robert A. Macleod, Catriona Jamieson, Leslie Crews> ;Cell Stem Cell. 2021 Apr 1
• 152 citations
  Multiple myeloma, version 3.2021
  Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Erica L. Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Y...> ;Journal of the National Comprehensive Cancer Network. 2020 Dec 2
• 347 citations
  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
  Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D....> ;Blood. 2020 Aug 20
• 49 citations
  A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
  Matthew S. Davids, Haesook T. Kim, Caitlin Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo O. Maegawa, Alexandra Savell, Michael Mazzeo, Adrienne Anderson, Alex...> ;Blood. 2020 Jun 11
• 10 citations
  Supportive Care in Multiple Myeloma.
  Amy Guzdar, Caitlin Costello> ;Current Hematologic Malignancy Reports. 2020 Mar 14
• 38 citations
  Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
  Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L. Gutierrez, Owen Chapman, Sandra E. Wiley, Joshua E. Mayfield, Vasudha Tandon, Edwin F. Juarez, Lukas Ch...> ;Proceedings of the National Academy of Sciences of the United States of America. 2019 Dec 3
• 3 citations
  Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
  Priya Hays, Caitlin Costello, Deepak Asudani> ;Future Oncology. 2019 Nov 27
• 10 citations
  The future of checkpoint inhibition in multiple myeloma
  Caitlin Costello> ;The Lancet. Haematology. 2019 Jul 18
• 21 citations
  INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
  Caitlin Costello, Faith E. Davies, Gordon Cook, Jorge Vela-Ojeda, Jim Omel, Robert M. Rifkin, Jesus G. Berdeja, Noemi Puig, Saad Z. Usmani, Katja Weisel, Jeffrey A. Zo...> ;Future Oncology. 2019 Feb 28
• 30 citations
  Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
  Paul G. Richardson, William I. Bensinger, Carol Ann Huff, Caitlin Costello, Nikoletta Lendvai, Jesus G. Berdeja, Larry D. Anderson, David S. Siegel, Daniel Lebovic, Su...> ;British Journal of Haematology. 2018 Mar 1
• 3 citations
  Therapy sequencing strategies in multiple myeloma: who, what and why?
  Caitlin Costello, Joseph R. Mikhael> ;Future Oncology. 2018 Jan 1
• 108 citations
  Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines
  Shaji Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henr...> ;Journal of the National Comprehensive Cancer Network. 2018 Jan 1
• Join now to see all

Journal Articles

• Immunotherapy in Multiple Myeloma  
  Costello C, J Hematol Mult Myeloma, 1/1/2016
• Multiple Myeloma, Version 22016  
  Anderson KC, Alsina M, Atanackovic D, Biermann JC, Chandler JC, Costello C, Bjulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff C..., J Natl Compr Canc Netw, 1/1/2015

Abstracts/Posters

• Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study.
  Rifkin RM, Davies FE, Palumo A, Zonder J, Girnius SK, Costello CL, Usmani SZ, Berdeja JG, Omel J, Thompson MA, Schwartz JS, Hajek R, Terpos E, Hungria V, Mateos MV, Co..., International Myeloma Working Group XVI, New Delhi, India, 1/1/2017
• Aberrant RNA Editing of GLI1 Promotes Malignant Regeneration in Multiple Myeloma. [abstract].
  Lazzari E, Delos Santos NP, Wu C, Leu H, Pineda G, Ali S, Costello C, Minden M, Chiaramonte R, Crews LA, Jamieson C, AACR; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, Washington, DC, 1/1/2017
• ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies.
  Lazzari E, Crews LA, Wu C, Leu H, Ali S, Chiaramonte R, Minden M, Costello C, Jamieson C, Cancer Res; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 1/16/2016
• Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.
  Goodman, AM, Choi MY, Wieduwilt MJ, Mulroney CM, Costello CL, Kurzrock R, Blood, 1/1/2016
• Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study.
  Rifkin RM, Davies FE, Palumo A, Zonder J, Girnius SK, Costello CL, Usmani SZ, Berdeja JG, Omel J, Thompson MA, Shah J, Schwartz JS, Hajek R, Terpos E, Hungria V, Mateo..., Blood, 1/1/2016
• Interim results of a multicenter phase I/Ib study of CTLA4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplan...
  Davids, MS, Haesook TK, Costello C, et al, 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, Turkey, 1/1/2015
• Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma; results from a multicenter phase 2 trial.
  Richardson, PG, Bensinger WI, Huff CA, Costello C, et al, International Myeloma Working Group Workshop – XV, Rome, Italy, 1/1/2015
• Updated results of a multicenter phaseI/Ib study of CTLA blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplanta...
  Davids, MS, Haesook TK, Costello C, et al, Haematologica; European Hematology Association, Vienna, Austria, 1/1/2015
• A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation.
  Davids, MS, Kim, Haesook T, Costello C, et al, Blood, 1/1/2015
• Targeting Cancer Stem Cell Survival in Plasma Cell Leukemia with a Pan-BCL2 Inhibitor.
  Lazzari E, Crews LA, Wu C, Leu H, Chiaramonte R, Minden MD, Costello C, Jamieson C, Blood, 1/1/2015
• Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 Trial.
  Richardson PG, Bensinger WI, Huff CA, Costello C, et al, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2015
• A multicenter Phase 1 of CTLA blockade with Ipilimumab for Relapsed Hematologic Malignancies after allogeneic Hematopoietic Cell Transplantation.
  Davids MS, Haesook TK, Costello C et al, 56th ASH Annual Meeting and Exposition, San Francisco, CA, 1/1/2014
• Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma: Preliminary Phase 2 Results.
  Vij R, Huff CA, Bensinger WI, Siegel DS, Jagannath S, Berdeja JG, Lendvai N, Lebovic D, Anderson LD, Costello C, et al, 56th ASH Annual Meeting and Exposition, San Francisco, CA, 1/1/2014
• Multiple Myeloma in Patients Under 40 Years Old is Associated with High-Risk Features and Worse Outcomes.
  Costello C, Blood; ASH Annual Meeting, 1/1/2013
• A Planned Phase I/IB Study of Ipilimumab in Relapsed Hematologic Malignancies After Allo-HCT.
  Davids MS, Bashey A, Costello C, et al, 2nd International Workshop in the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, NIH, Bethesda, MD, 1/1/2012
• Impact of Deletion 17p on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
  Costello C, Corringham S, Li H, Messer K, Ball ED, Blood; ASH Annual Meeting, 1/1/2012
• Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.
  Costello C, Holman PR, Demagalhaes-Silverman M, Corringham S, Castro J, Ball ED, Blood; ASH Annual Meeting, 1/1/2011
• Join now to see all

Lectures

• Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Plasma Cell Disorders, Myeloma 
  Brisbane, Australia - 1/1/2016
• Treatment of Relapsed/Refractory Multiple Myeloma 
  San Francisco, CA - 1/1/2016
• Myeloma and the Ever-Complicated Immune System 
  La Jolla, CA - 1/1/2015
• Multiple Myeloma: The Basics and Beyond 
  San Diego, CA - 1/1/2015
• Myeloma: The Basics 
  La Jolla, CA - 1/1/2014
• Oncologic Emergencies 
  San Diego, CA - 1/1/2013
• Multiple Myeloma: What’s new in 2012 
  La Jolla, CA - 1/1/2012
• Join now to see all

Other

• Managing neutropenic fever in oncology patients. 
  Wooten D, Chang W, Costello C, ACP Hospitalist
  1/1/2016
• Oncologic Emergencies and the Family Physician. 
  Costello C, Maryland Family Doctor, Spring
  1/1/2014